Krystal Biotech

General Information
Business:

We are a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. We have developed a proprietary gene therapy platform, which we refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which we believe there are no known effective treatments. We are initially using the STAR-D platform to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene, and plan to leverage our platform to expand our pipeline to include other dermatological indications in the future.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 7
Founded: 2015
Contact Information
Address 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
Phone Number (412) 586-5830
Web Address http://www.krystalbio.com
View Prospectus: Krystal Biotech
Financial Information
Market Cap $96.4mil
Revenues $0 mil (last 12 months)
Net Income $-2.2 mil (last 12 months)
IPO Profile
Symbol KRYS
Exchange NASDAQ
Shares (millions): 4.0
Price range $10.00 - $10.00
Est. $ Volume $39.6 mil
Manager / Joint Managers Ladenburg Thalmann
CO-Managers -
Expected To Trade: 9/20/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change